Insights

Recent Mergers AVROBIO has recently been involved in merger activities with companies like Tectonic Therapeutic and Novartis, indicating potential synergies and opportunities for collaboration with these merged entities.

Personalized Gene Therapy AVROBIO's focus on personalized gene therapy presents a unique approach to tackling genetic diseases through hematopoietic stem cell gene therapy, opening doors for partnerships with healthcare providers seeking innovative treatment solutions.

Technology Stack AVROBIO employs a diverse tech stack including 33Across, Akamai, and Adobe Tag Manager, suggesting a reliance on cutting-edge technologies that could be leveraged by tech companies offering complementary solutions.

Financial Transactions Financial activities such as selling assets to Novartis and being acquired by Novartis for $88M reveal a strong financial position, making AVROBIO an attractive target for financial institutions or investors seeking strategic investments in biotech.

Market Position With a revenue range of $10M - 50M and a unique gene therapy platform, AVROBIO competes in a market alongside companies like CRISPR Therapeutics and Editas Medicine, suggesting potential collaborations, acquisitions, or competitive strategies to explore.

Similar companies to AVROBIO

AVROBIO Tech Stack

AVROBIO uses 8 technology products and services including 33Across, Akamai, Slick, and more. Explore AVROBIO's tech stack below.

33Across
Advertising
Akamai
Content Delivery Network
Slick
Javascript Libraries
WP Engine
Platform As A Service
Adobe Tag Manager
Tag Management
RankMath SEO
Web Platform Extensions
Apache
Web Servers
ShareThis
Widgets

Media & News

AVROBIO's Email Address Formats

AVROBIO uses at least 1 format(s):

AVROBIO Email Formats	Example	Percentage
First.Last@avrobio.com	John.Doe@avrobio.com	95%
FLast@avrobio.com	JDoe@avrobio.com	2%
Last@avrobio.com	Doe@avrobio.com	2%
First.L@avrobio.com	John.D@avrobio.com	1%

Frequently Asked Questions

Where is AVROBIO's headquarters located?

AVROBIO's main headquarters is located at 100 Technology Sq 6th Floor Cambridge, Massachusetts 02139 US. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is AVROBIO's phone number?

You can contact AVROBIO's main corporate office by phone at

+1-781-264-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is AVROBIO's stock symbol?

AVROBIO is a publicly traded company; the company's stock symbol is TECX.

What is AVROBIO's official website and social media links?

AVROBIO's official website is avrobio.com and has social profiles on LinkedIn.

How much revenue does AVROBIO generate?

As of October 2024, AVROBIO's annual revenue reached $15M.

What is AVROBIO's SIC code NAICS code?

AVROBIO's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does AVROBIO have currently?

As of October 2024, AVROBIO has approximately 51 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Legal Officer: S. A.Chief Medical Officer: A. A.Chief Medical Officer: E. R.. Explore AVROBIO's employee directory with LeadIQ.

What industry does AVROBIO belong to?

AVROBIO operates in the Biotechnology Research industry.

What technology does AVROBIO use?

AVROBIO's tech stack includes 33AcrossAkamaiSlickWP EngineAdobe Tag ManagerRankMath SEOApacheShareThis.

What is AVROBIO's email format?

AVROBIO's email format typically follows the pattern of . Find more AVROBIO email formats with LeadIQ.

How much funding has AVROBIO raised to date?

As of October 2024, AVROBIO has raised $60M in funding. The last funding round occurred on Feb 01, 2018 for $60M.

AVROBIO

Biotechnology ResearchMassachusetts, United States51-200 Employees

Our vision is to bring personalized gene therapy to the world. We target the root cause of genetic disease by introducing a functional copy of the affected gene into patients’ own hematopoietic stem cells (HSCs), with the goal of durably expressing the therapeutic protein throughout the body, including the central nervous system. Our first-in-class pipeline includes clinical programs for Gaucher disease and Hunter syndrome, as well as a preclinical program for Pompe disease. Our proprietary plato® gene therapy platform is scalable for planned global commercialization. We are headquartered in Cambridge, Mass. For additional information, visit avrobio.com, and follow us on Twitter and LinkedIn.

Company Overview

Headquarters: 100 Technology Sq 6th Floor Cambridge, Massachusetts 02139 US
Phone number: ✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
+1-781-264-****
Website: avrobio.com
SIC Code: 8733 - Noncommercial Research Organizations
Stock Symbol: TECX
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 51-200

Media & News

Funding & Financials

$60M
AVROBIO has raised a total of $60M of funding over 3 rounds. Their latest funding round was raised on Feb 01, 2018 in the amount of $60M.
$10M$50M
AVROBIO's revenue is in the range of $10M$50M

Funding & Financials

$60M
AVROBIO has raised a total of $60M of funding over 3 rounds. Their latest funding round was raised on Feb 01, 2018 in the amount of $60M.
$10M$50M
AVROBIO's revenue is in the range of $10M$50M

Company Leadership

S. A.
Chief Legal Officer
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
A. A.
Chief Medical Officer
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
E. R.
Chief Medical Officer
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
K. D.
Chief Of Staff
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
S. G.
Vice President , Head Of Human Resources
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Employee Directory

R. P.
Vp, Toxicology, Research And Preclinical Development
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
D. G.
Vice President, Global Manufacturing And Supply Chain
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
K. D.
Chief Of Staff
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
M. A.
Vice President Clinical Development
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
M. T.
Talent Management Head And Human Resources Bp
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for AVROBIO and Millions of Other Companies
Sign up for full access to AVROBIO information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Go to Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to AVROBIO

CRISPR Therapeutics

Sarepta Therapeutics

MeiraGTx

Editas Medicine

uniQure

Orchard Therapeutics - U.S.

Jaguar Gene Therapy

Passage Bio

bluebird bio

AVROBIO Tech Stack

Media & News

Ostrowski leaves AVROBIO, Inc. as President, Interim Chief Executive Officer and Chief Financial Officer.

AVROBIO, Inc. recognized as Corporate Activity and Growth category.

AVROBIO, Inc. merged with Tectonictx on Jun 21st '24.

AVROBIO, Inc. sold assets to Cystinosis on May 1st '23.

Novartis Pharma AG acquired AVROBIO, Inc. for $88M on Oct 1st '23.

Petersen leaves AVROBIO, Inc. as Chief Business Officer.

AVROBIO, Inc. sold assets to Novartis Pharma AG in the amount of $87.5M on May 22nd '23.

AVROBIO's Email Address Formats

Frequently Asked Questions

Where is AVROBIO's headquarters located?

What is AVROBIO's phone number?

What is AVROBIO's stock symbol?

What is AVROBIO's official website and social media links?

How much revenue does AVROBIO generate?

What is AVROBIO's SIC code NAICS code?

How many employees does AVROBIO have currently?

What industry does AVROBIO belong to?

What technology does AVROBIO use?

What is AVROBIO's email format?

How much funding has AVROBIO raised to date?

AVROBIO

Company Overview

Media & News

Ostrowski leaves AVROBIO, Inc. as President, Interim Chief Executive Officer and Chief Financial Officer.

AVROBIO, Inc. recognized as Corporate Activity and Growth category.

AVROBIO, Inc. merged with Tectonictx on Jun 21st '24.

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?